Cargando…
Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204919/ https://www.ncbi.nlm.nih.gov/pubmed/32332035 http://dx.doi.org/10.1136/bmjgh-2019-002061 |
Sumario: |
---|